Scilit logo
  • Rankings
  • Search Publications
    Cited-by Search
  • Sources
  • Publishers
  • Scholars
    Top Cited Scholars
  • Organizations
  • Scilit
    About Us
    Advisory Board
    Data Sources
    Career
    Support / Contact
    User Guide
    Publisher User
    Search Function
    Rankings Function
    API Resource
    Scilit Knowledge
    Metrics
    Scilit Recognitions
    Publications Classification
    Media
    News
    Blog
Register
  1. Home
  2. Publications
  3. Table S3 from Nivolumab Reaches Brain Lesions in Patients with Recurrent Glioblastoma and Induces T-cell Activity and Upregulation of Checkpoint Pathways
  1. Home
  2. Publications
  3. Table S3 from Nivolumab Reaches Brain Lesions in Patients with Recurrent Glioblastoma and Induces T-cell Activity and Upregulation of Checkpoint Pathways

Table S3 from Nivolumab Reaches Brain Lesions in Patients with Recurrent Glioblastoma and Induces T-cell Activity and Upregulation of Checkpoint Pathways

Authors:
  • SSSigne K. Skadborg
    Signe K. Skadborg
  • SMSimone Maarup
    Simone Maarup
  • ADArianna Draghi
    Arianna Draghi
  • ABAnnie Borch
    Annie Borch
  • SHSille Hendriksen
    Sille Hendriksen
  • FMFilip Mundt
    Filip Mundt
  • VPVilde Pedersen
    Vilde Pedersen
  • MMMatthias Mann
    Matthias Mann
  • ICIb J. Christensen
    Ib J. Christensen
  • JSJane Skjøth-Ramussen
    Jane Skjøth-Ramussen
  • CYChristina W. Yde
    Christina W. Yde
  • BKBjarne W. Kristensen
    Bjarne W. Kristensen

Open Access
Publisher website
Google Scholar
  • 17 June 2026
    • other
    • Published by American Association for Cancer Research (AACR)
    • DOI:10.1158/2326-6066.32698349
Abstract
No abstract available
Keywords
  • CANCER
Scilit logo

Have questions? Email us at support@scilit.com

© 2026 MDPI (Basel, Switzerland) unless otherwise stated.

MDPI initiatives

  • MDPI Journals
  • MDPI Books
  • Sciforum
  • Proceedings Series
  • Preprints.org
  • SciProfiles
  • Encyclopedia
  • JAMS

Legal

  • Privacy
  • Terms
  • About
  • Contact
  • Disclaimer

Follow us

  • facebook icon
  • x icon
  • linkedin icon

Join us

  • Career

© 2026 MDPI (Basel, Switzerland) unless otherwise stated.